China Health Industries Holdings, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2019
November 14, 2019 at 09:54 am EST
Share
China Health Industries Holdings, Inc. announced earnings results for the first quarter ended September 30, 2019. For the first quarter, the company announced sales was USD 2.053 million compared to USD 2.141 million a year ago. Operating income was USD 1.038 million compared to USD 912,570 a year ago. Net income was USD 756,574 compared to USD 632,214 a year ago. Basic earnings per share from continuing operations was USD 0.0115 compared to USD 0.0096 a year ago. Diluted earnings per share from continuing operations was USD 0.012 compared to USD 0.01 a year ago.
China Health Industries Holdings, Inc. is a manufacturer of health food products. The Company's principal business operations are conducted through its subsidiaries: Harbin Humankind Biology Technology Co., Limited (Humankind) and Heilongjiang Huimeijia Pharmaceutical Co., Ltd (HLJ Huimeijia). The Company has three operating segments: Humankind, HLJ Huimeijia and others. Humankind is engaged in the manufacturing and sale of health products. HLJ Huimeijia is engaged in the manufacturing and distribution of tincture; ointments; rubber paste, including hormones; topical solution, suppositories, liniment, including traditional Chinese medicine extractions; enemas, and oral liquids. As of June 30, 2016, the Company, through Humankind manufactured and sold 14 health supplement products. As of June 30, 2016, the Company, through HLJ Huimeijia manufactured and sold 21 products. The Company's products are sold through sales agents.
CHINA HEALTH INDUSTRIES HOLDINGS, INC. 
